Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL

Journal of Immunology

Volumn 175, Issue 2, 2005, Pages 1301-1309

  Lotz, Carina ^a,d   Mutallib, Sarah Abdel ^a   Oehlrich, Nicole ^a   Liewer, Ulrike ^a   Ferreira, Edite Antunes ^a   Moos, Marion ^c   Hundemer, Michael ^c   Schneider, Sandra ^b   Strand, Susanne ^a   Huber, Christoph ^a   Goldschmidt, Hartmut ^c   Theobald, Matthias ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Ganymed Pharmaceuticals   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; POSITIVE REGULATORY DOMAIN I BINDING FACTOR 1; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CANCER IMMUNOTHERAPY; CELL KILLING; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

EID: 23244447258     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.2.1301     Document Type: Article

References (58)

1. Blade, J., D. H. Vesole, and M. Gertz. 2003. Controversy in hematology: transplantation for multiple myeloma: who, when, how often: high-dose therapy in multiple myeloma. Blood 102: 3469-3477.
2. Gahrton, G., H. Svensson, M. Cavo, J. Apperly, A. Bacigalupo, B. Bjorkstrand, J. Blade, J. Cornelissen, A. de Laurenzi, T. Facon, et al. 2001. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br. J. Haematol. 113: 209-216.
3. Tricot, G., D. H. Vesole, S. Jagannath, J. Hilton, N. Munshi, and B. Barlogie. 1996. Graft-versus-myeloma effect: proof of principle. Blood 87: 1196-1198.
4. Le Blanc, R., S. Montminy-Metivier, R. Belanger, L. Busque, D. Fish, D. C. Roy, J. Kassis, J. Boileau, R. Lavallee, D. Belanger, et al. 2001. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant. 28: 841-842,
5. + T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 63: 2561-2568.
6. Salama, M., T. Nevill, D. Marcellus, P. Parker, M. Johnson, A. Kirk, D. Porter, S. Giralt, J. E. Levine, W. Drobyski, et al. 2000. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 26: 1179-1184.
7. Lokhorst, H. M., A. Schattenberg, J. J. Cornelissen, M. H. van Oers, W. Fibbe, I. Russell, N. W. Donk, and L. F. Verdonck. 2000. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J. Clin. Oncol. 18: 3031-3037.
8. Stevenson, F. K., and K. C. Anderson. 2000. Preparing the ground for vaccination against multiple myeloma. Immunol. Today 21: 170-171.
9. Pellat-Deceunynck, C. 2003. Tumour-associated antigens in multiple myeloma. Br. J. Haematol. 120: 3-9.
10. Van Baren, N., F. Brasseur, D. Godelaine, G. Hames, A. Ferrant, F. Lehmann, M. Andre, C. Ravoet, C. Doyen, G. C. Spagnoli, et al. 1999. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94: 1156-1164.
11. Brossart, P., A. Schneider, P. Dill, T. Schammann, F. Grunebach, S. Wirths, L. Kanz, H. J. Buhring, and W. Brugger. 2001. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 61: 6846-6850.
12. Milazzo, C., V. L. Reichardt, M. R. Müller, F. Grünebach, and P. Brossart. 2003. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101: 977-982.
13. Theobald, M., J. Biggs, D. Dittmer, A. J. Levine, and L. A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92: 11993-11997.
14. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, et al. 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2: 962-970.
15. Shapiro-Shelef, M., and K. Calame. 2004. Plasma cell differentiation and multiple myeloma. Curr. Opin. Immunol. 16: 226-234.
16. Reimold, A. M., N. N. Iwakoshi, J. Manis, P. Vallabhajosyula, E. Szomolanyi-Tsuda, E. M. Gravallese, D. Friend, M. J. Grusby, F. Alt, and L. H. Glimcher. 2001. Plasma cell differentiation requires the transcription factor XBP-1. Nature 412: 300-307.
17. Turner, C. A., Jr., D. H. Mack, and M. M. Davis. 1994. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 77: 297-306.
18. 2-co- stimulated B lymphocytes. Eur. J. Immunol. 26: 268-271.
19. Angelin-Duclos, C., G. Cattoretti, K. I. Lin, and K. Calame. 2000. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J. Immunol. 165: 5462-5471.
20. Shapiro-Shelef, M., K. I. Lin, L. J. McHeyzer-Williams, J. Liao, M. G. McHeyzer-Williams, and K. Calame. 2003. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 19: 607-620.
21. Ghosh, N., I. Gyory, G. Wright, J. Wood, and K. L. Wright. 2001. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J. Biol. Chem. 276: 15264-15268.
22. Borson, N. D., M. Q. Lacy, and P. J. Wettstein. 2002. Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood 100: 4629-4639.
23. Nagy, M., B. Chapuis, and T. Matthes. 2002. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. Br. J. Haematol. 116: 429-435.
24. Zhan, F., E. Tian, K. Bumm, R. Smith, B. Barlogie, and J. Shaughnessy, Jr. 2003. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101: 1128-1140.
25. Chang, D. H., C. Angelin-Duclos, and K. Calame. 2000. BLIMP-1: trigger for differentiation of myeloid lineage. Nat. Immunol. 1: 169-176.
26. Liou, H. C., R. Eddy, T. Shows, B. Lisowska-Grospierre, C. Griscelli, C. Doyle, J. Mannhalter, M. Eibl, and L. H. Glimcher. 1991. An HLA-DR α promoter DNA-binding protein is expressed ubiquitously and maps to human chromosomes 22 and 5. Immunogenetics 34: 286-292.
27. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185: 833-841.
28. Sherman, L. A., S. V. Hesse, M. J. Irwin, D. La Face, and P. Peterson. 1992. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 258: 815-818.
29. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, and J. Ruppert. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153: 5586-5592.
30. + T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA 88: 11276-11280.
31. Lotz, C., E. A. Ferreira, I. Drexler, S. A. Mutallib, C. Huber, G. Sutter, and M. Theobald. 2004. Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man. Int. J. Cancer 108: 571-579.
32. Kuckelkorn, U., E. A. Ferreira, I. Drung, U. Liewer, P. M. Kloetzel, and M. Theobald. 2002. The effect of the interferon-γ-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context. Eur. J. Immunology. 32: 1368-1375.
33. Kuball, J., M. Schuler, F. E. Antunes, W. Herr, M. Neumann, L. Obenauer-Kutner, L. Westreich, C. Huber, T. Wölfel, and M. Theobald. 2002. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther. 9: 833-843.
34. Goidin, D., A. Mamessier, M. J. Staquet, D. Schmitt, and O. Berthier-Vergnes. 2001. Ribosomal 18S RNA prevails over glyceraldehyde-3- phosphate dehydrogenase and β-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal. Biochem. 295: 17-21.
35. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152: 163-175.
36. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.
37. Chen, W., J. W. Yewdell, R. L. Levine, and J. R. Bennink. 1999. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J. Exp. Med. 189: 1757-1764.
38. Munshi, N. C., T. Hideshima, D. Carrasco, M. Shammas, D. Auclair, F. Davies, N. Mitsiades, C. Mitsiades, R. S. Kim, C. Li, et al. 2004. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 103: 1799-1806.
39. Meadows, L., W. Wang, J. M. den Haan, E. Blokland, C. Reinhardus, J. W. Drijfhout, J. Shabanowitz, R. Pierce, A. I. Agulnik, C. E. Bishop, et al. 1997. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6: 273-281.
40. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.
41. Kokura, K., T. Kishimoto, and T. Tamura. 2000. Identity between rat htf and human xbp-1 genes: determination of gene structure, target sequence, and transcription promotion function for HTF. Gene 241: 297-307.
42. Keller, A. D., and T. Maniatis. 1991. Identification and characterization of a novel repressor of β-interferon gene expression. Genes Dev. 5: 868-879.
43. Kishimoto, T., K. Kokura, N. Ohkawa, Y. Makino, M. Yoshida, S. Hirohashi, S. Niwa, M. Muramatsu, and T. Tamura. 1998. Enhanced expression of a new class of liver-enriched b-Zip transcription factors, hepatocarcinogenesis-related transcription factor, in hepatocellular carcinomas of rats and humans. Cell Growth Differ. 9: 337-344.
44. Medema, J. P., D. H. Schuurhuis, D. Rea, J. van Tongeren, J. de Jong, S. A. Bres, S. Laban, R. E. Toes, M. Toebes, T. N. Schumacher, et al. 2001. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 194: 657-667.
45. Shresta, S., T. A. Graubert, D. A. Thomas, S. Z. Raptis, and T. J. Ley. 1999. Granzyme A initiates an alternative pathway for granule-mediated apoptosis. Immunity 10: 595-605.
46. Richardson, P. G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, et al. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348: 2609-2617.
47. Lee, A. H., N. N. Iwakoshi, K. C. Anderson, and L. H. Glimcher. 2003. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA 100: 9946-9951.
48. Kallies, A., J. Hasbold, D. M. Tarlinton, W. Dietrich, L. M. Corcoran, P. D. Hodgkin, and S. L. Nutt. 2004. Plasma cell ontogenity defined by quantitative changes in Blimp-1 expression. J. Exp. Med. 200: 967-977.
49. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van der Valk, and T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2: 957-961.
50. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22: 117-129.
51. Stauss, H. J. 1999. Immunotherapy with CTLs restricted by nonself MHC. Immunol. Today 20: 180-183.
52. Holler, P. D., P. O. Holman, E. V. Shusta, S. O'Herrin, K. D. Wittrup, and D. M. Kranz. 2000. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA 97: 5387-5392.
53. Kessels, H. W., M. D. van den Boom, H. Spits, E. Hooijberg, and T. N. Schumacher. 2000. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA 97: 14578-14583.
54. Chames, P., R. A. Willemsen, G. Rojas, D. Dieckmann, L. Rem, G. Schuler, R. L. Bolhuis, and H. R. Hoogenboom. 2002. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 169: 1110-1118.
55. Heemskerk, M. H., M. Hoogeboom, R. A. de Paus, M. G. Kester, M. A. van der Hoorn, E. Goulmy, R. Willemze, and J. H. Falkenburg. 2003. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved α joining region. Blood 102: 3530-3540.
56. Mittrucker, H. W., T. Matsuyama, A. Grossman, T. M. Kundig, J. Potter, A. Shahinian, A. Wakeham, B. Patterson, P. S. Ohashi, and T. W. Mak. 1997. Requirement for the transcription factor LSIRF/TRF4 for mature B and T lymphocyte function. Science 275: 540-543.
57. Iida, S., P. H. Rao, M. Butler, P. Corradini, M. Boccadoro, B. Klein, R. S. Chaganti, and R. Dalla-Favera. 1997. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat. Genet. 17: 226-230.
58. Underhill, G. H., D. George, E. G. Bremer, and G. S. Kansas. 2003. Gene expression profiling, reveals a highly specialized genetic program of plasma cells. Blood 101: 4013-4021.